Pfizer cuts discounts from January 1

Business Pharmacists will have to pay more for Pfizer’s patent products next year as part of the manufacturer’s new discount scheme.
Forgotten your password?
The page you are looking for is only available to logged in members of Chemist+Druggist.
Not a member yet?
Register now
If you are not a registered user, then please sign up here. Registering is free and takes just seconds. It gives you access to up-to-the minute news alerts and analysis, all our top bloggers.
If you experience any difficulties logging in or registering, or have any other questions, please contact Chemist+Druggist at haveyoursay@chemistanddruggist.co.uk
Comment on this article
You are not currently logged in. Login or register
Your Comments
R Cygan, Superintendent
Posted on 6 December 2011.
Another interesting move from Pfizer - the "nail in the pharmacy coffin" experts. Clearly, its a move to squeeze every penny out of the patented products before their forthcoming demise. With Xalatan coming off patent in the New Year, Lipitor in May and not long after Viagra and Boehringer stealing a march on them with dabigatran (Pradaxa), its not surprising. Playing devils advocate - It makes sound commercial sense on their part. However, cnce again, the loser is pharmacy, despite Pfizers deluded claims that we all love the company and sponsoring the odd event, will compensate for everyting. Anyone who attended the Pharmacy Show in October would have noticed two things about the Pfizer stand. Firstly, it was by far the biggest and secondly it was by far the emptiest! Good job the employees manning the stand had their mobile phones to play with! In fairness, we have seen similar reductions in discounts from other manufacturers as they moved to dtp, but unfortunately for Pfizer, they will always be blamed more the others as they set the whole proverbial 'dtp ball in motion'. Pharmacists showed their feelings towards Lipitor and Pfizer when Teva briefly launced the generic. Sales of the generic exceeded £20m in one day. It is clear to see what an extra 1% will mean for Pfizer.
However, the PSNC must now be seen to be acting in the ineterests of all contractors. This can all be offset with the appropriiate adjustment in discount clawback. As contractors, we have seen signifcant reductions in discounts due to dtp, from ALL those manufacturers who have made that move, but we have not seen corresponding reductions in discount clawback. NET EFFECT = FALL IN INCOME.
PSNC - the ball is now firmly in your court.
Top
Dhanoa, Superintendent
Posted on 06/12/11 15:45 in reply to R Cygan.
Totally agree with R Cygan. Our average clawback is over 10.25% how does that equate to a fair return when on most DTP lines pharmacy contractors are actually making a loss as apposed to a profit?? This move by Pfizer is certainly a nail in the coffin but I don't mean pharmacy I mean in the hearts and minds of pharmacy contractors and their already sparse support towards Pfizer.
Top
Clive Hodgson, Community pharmacist
Posted on 7 December 2011.
"Mr Wilson (Pfizer) also stressed that the company was "committed to continuing to support community pharmacy"."
----------------------------------------------------------------------------------------------------------------
Cynical B******t methinks.
Top
Michael Ball, Community pharmacist
Posted on 16 December 2011.
Its a shame we cannot opt to decline the offer of discount from pfizer, and simply endorse the script DNG. At least that way, as Dhanoa states, we wouldnt be on average 2.75% out of pocket everytime we dispense one of these pfizer products.
Top

Please note You must be a registered user of Chemist+Druggist and logged in to add comments. Opinions expressed here are those of the writers and do not necessarily reflect those of Chemist+Druggist. Comments are considered in the public domain and may be used in future Chemist+Druggist coverage. We accept no responsibility, legal or otherwise, for the accuracy or the content of member comments.



 

Job of the week

Pharmacist & Technicians

Various locations

£45k + performance bonus

Follow C+D Jobs on